{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-011878","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2025-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.170354+00:00","generated_at":"2026-05-20T22:02:27.747550+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protagenic Therapeutics receives $3.1M from warrant exchanges and exercises","bullets":["Warrant exchanges and exercises over the last four trading days generated $3.1M in cash.","Proceeds will fund working capital and advance peptide-based drug candidates for CNS disorders.","Company previously announced business combination with Phytanix Bio Inc. on May 19, 2025.","Combined entity has six drug programs spanning stress, epilepsy, obesity, and other indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-011878","json":"https://secwatch.observer/filing/0001641172-25-011878.json","markdown":"https://secwatch.observer/filing/0001641172-25-011878.md","text":"https://secwatch.observer/filing/0001641172-25-011878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011878/0001641172-25-011878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011878/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T22:02:27.747550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}